Collectively, SYNCHRONIZE-1 and SYNCHRONIZE-MASLD show the potential benefits of glucagon/GLP-1 dual agonism for people living with obesity and people with MASLD with evidence of inflammation and or fibrosis
( i ) Fasting plasma GIP (n = 5 per group), ( j ) total GLP-1 (CON n = 9, Gipr AP-KO n = 8), ( k ) insulin (CON n = 5, GIPR AP-KO n = 4), (l) food intake post IPGTT (CON n = 6, Gipr AP-KO n = 6), ( m ) ad lib fed blood glucose (CON n = 6, Gipr AP-KO n = 6), (n) RER (time x group F(24, 168) = 1.739 p = 0.023), ( o ) energy expenditure (with ANCOVA using BW as covariate), ( p ) ambulatory activity (x beam breaks)
This focuses on achieving Metabolic Flexibility: your bodys ability to efficiently switch between burning fuel and stored fat, ensuring your results last a lifetime.
Mitochondrial morphology and mitophagy in heart diseases: qualitative and quantitative analyses using transmission electron microscopy
This route of administration represents the gold standard for peptide delivery
In 1983, manual shakers were not available commercially
